IntelGenx Corp.
IntelGenx Appoints Andre Godin as New Executive Vice-President and Chief Financial Officer
DGAP-News: IntelGenx Corp. / Key word(s): Miscellaneous 2015-07-20 / 22:01 --------------------------------------------------------------------- Saint Laurent, Quebec--(Newsfile Corp. - July 20, 2015) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the 'Company' or 'IntelGenx') today announced that it entered into an employment agreement with Andre Godin, CPA, CA as Executive Vice-President and Chief Financial Officer effective August 24, 2015. The board has appointed Mr. Godin as Chief Financial Officer effective immediately. The board of directors granted stock options to acquire 600,000 common shares under the 2006 Stock Option Plan to Mr. Godin as per his employment agreement. The options have an exercise price of US$0.58(CAD$0.75), vest over a period of two years at the rate of 25% every six months, and expire on July 20, 2020. Mr. Godin has more than 25 years experience in the Biotech/Pharma industry. Most recently, he served as Interim CEO and CFO of Neptune Technologies and Bioresources Inc. and both of its subsidiaries Acasti and NeuroBioPharm. He started with Neptune in 2003 as Vice President, Administration and Finance and was named its Chief Financial Officer in 2008. Prior to joining Neptune, Mr. Godin was president of a dietary supplement corporation and a corporate controller for a pharmaceutical corporation in OTC products. 'Andre brings a wealth of experience in general and financial management to our team,' said Dr. Horst G. Zerbe, President and CEO of IntelGenx. 'During his tenure as the CFO of a NASDAQ and TSX listed company, he raised in excess of $100 million. His vast experience with capital markets both in the United States and Canada will be a key factor in the company's future growth. We are very fortunate to have found such a strong leader to join our team.' Mr. Godin is a member of the Canadian Chartered Professional Accountants and the Canadian Institute of Chartered Accountants. He holds a Bachelor of Business Administration degree from Universite du Quebec à Montreal. Mr. Godin will join Dr. Horst Zerbe for the upcoming investor update call of the company in the second week of August. About IntelGenx: IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com. CONTACT: Dr. Horst G. Zerbe, President and CEO horst@IntelGenx.com T: +1 514-331-7440 F: +1 514-331-0436 www.intelgenx.com Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/16362 News Source: Newsfile --------------------------------------------------------------------- 2015-07-20 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: IntelGenx Corp. Canada ISIN: US45822R1014 End of News DGAP News-Service --------------------------------------------------------------------- 379397 2015-07-20
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found